THE National Immunisation Program (NIP) has expanded access to GSK's Shingrix vaccine for Australians aged 18 to 64 who are at moderate-to-high risk of shingles due to underlying conditions.
The Australian Technical Advisory Group on Immunisation recommended the expansion, which aims to help those with compromised immune systems.
Crohn's and Colitis Australia CEO, Leanne Raven, supported the expansion, noting that people with autoimmune conditions are at greater risk.
GSK Australia's Dr Alan Paul echoed these sentiments, praising the govt's decision to protect high-risk groups from the painful viral infection.
"This NIP expansion is evidence that the government is committed to providing more protection for those adults considered at increased risk of herpes zoster when it comes to vaccine preventable diseases like shingles," commented Dr Paul.
The above article was sent to subscribers in Pharmacy Daily's issue from 23 Sep 24
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 23 Sep 24
